139183-89-4

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl imidazo[1,5-a]pyridine-6-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow it to be incorporated into the molecular frameworks of new drugs, contributing to their therapeutic efficacy and selectivity.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Methyl imidazo[1,5-a]pyridine-6-carboxylate is employed as a pharmacophore. Its ability to interact with biological targets makes it instrumental in the discovery and optimization of new drug candidates, facilitating the advancement of novel therapeutic agents.
Used in Organic Compound Synthesis:
Beyond its pharmaceutical applications, Methyl imidazo[1,5-a]pyridine-6-carboxylate is also used in the synthesis of a variety of organic compounds. Its versatility in chemical reactions enables the creation of diverse molecules with potential applications in various industries, including materials science, agrochemicals, and specialty chemicals.
Used in Drug Development:
Methyl imidazo[1,5-a]pyridine-6-carboxylate is leveraged in drug development for its potential to treat a range of diseases and medical conditions. Its diverse pharmacological properties make it a promising candidate for the development of new therapeutic agents, offering hope for improved treatments and patient outcomes.

Upstream product

• 22794-96-3 methyl 6-hydroxyiminomethylnicotinate 
• 139183-87-2 methyl 6-(aminomethyl)nicotinate 
• 139183-88-3 methyl 6-formylaminomethylnicotinate 

Downstream Products

• 1362159-55-4 N-{[4-(benzenesulfonyl)phenyl]methyl}imidazo[1,5-a]pyridine-6-carboxamide 
• 1354904-63-4 methyl 3-{[3-(methoxycarbonyl)-4-[(propylcarbamoyl)amino]phenyl]carbonyl}imidazo[1,5-a]pyridine-6-carboxylate 
• 1354904-60-1 3-[(4-amino-3-carboxyphenyl)carbonyl]imidazo[1,5-a]pyridine-6-carboxylic acid 
• 256935-76-9 imidazo[1,5-a]pyridine-6-carboxylic acid 

Relevant academic research and scientific papers

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Synthesis and biological evaluation of 2-Indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent

A series of indole containing oxazolines has been discovered as a result of structural modifications of the lead compound A-105972. The compounds exert their anticancer activity through inhibition of tubulin polymerization by binding at the colchicine site. A-289099 was identified as an orally active antimitotic agent active against various cancer cell lines including those that express the MDR phenotype. The anticancer activity, pharmacokinetics, and an efficient and enantioselective synthesis of A-289099 are described.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

We prepared a novel series of conformationally restricted fused imidazole derivatives 4b, 4c and 4d (possessing 4,5,6,7-tetrahydroimidazo[4,5- c]pyridine and substituted 4,5,6,7-tetrahydro-1H-benzimidazole for 4b, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine for 4c and 5,6,7,8- tetrahydroimidazo[1,5-a]pyridine for 4d as a basic amine part and (2- methoxyphenyl)aminocarbonyl group as an aromatic-carbonyl part). Their activities were then evaluated as an 5-hydroxytryptamine (5-HT3) receptor antagonist which may be useful for the treatment of irritable bowel syndrome (IBS) as well as for nausea and vomiting associated with cancer chemotherapy. The most potent compound was N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H- benzimidazole-5-carboxamide 14 in this series with an ID50 value of 0.32 μg/kg on the von Bezold-Jarisch reflex in rats and an IC50 value of 0.43 μM on the isolated colonic contraction in guinea pig, approximately ten and two times more potent than ondansetron 1, respectively. The structure- activity relationships (SAR) study suggested that the high potency of 14 may be attributed to the suitable position and direction of the N-C-N centroid in the conformationally restricted imidazole ring against the planar (2-methoxy- phenyl)aminocarbonyl part in the binding of 14 to the receptor.

TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AND SALTS THEREOF

Tetrahydroimidazopyridine derivatives which are useful for the treatment of irritable bowel syndrome are provided and can be represented by the following formula, STR1 wherein either one of X and Y is nitrogen and the other one is a radical represented by the formula = C(R 1)--; and R is a radical of the formula STR2 a radical of the formula STR3 or a radical of the formula STR4 in which R 1, R. sup.2 and R 3 are same or different and represent hydrogen or a C. sub. 1-C 6 alkyl group, and salts thereof. Pharmaceutical compositions are also provided.